期刊
NPJ PRECISION ONCOLOGY
卷 5, 期 1, 页码 -出版社
NATURE RESEARCH
DOI: 10.1038/s41698-021-00197-w
关键词
-
类别
资金
- Ludwig Center at Harvard
- National Foundation for Cancer Research
- Jane's Trust Foundation
- Advanced Medical Research Foundation
- U.S. National Cancer Institute and Department of Defense Breast Cancer Research Innovator Award
- Department of Defense Breast Cancer Research Program Breakthrough Award [BC190827]
- A*STAR NSS
- NIH [T32HL007627, T32CA251062]
The study showed that a single dose of bevacizumab can reduce the density of angiopoietin-2-positive vessels and increase the infiltration of immune cells in patients with primary triple-negative breast cancer, suggesting a potential rationale for combining bevacizumab with immune checkpoint blockers in neoadjuvant treatment to improve efficacy.
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据